메뉴 건너뛰기




Volumn 46, Issue 3, 2013, Pages 299-303

In vitro activity of antimicrobial combinations against multidrug-resistant Pseudomonas aeruginosa

Author keywords

Antimicrobial synergy; Beta lactam agents; Fosfomycin; Pseudomonas aeruginosa; Rifampin; Tobramycin

Indexed keywords

AMINOGLYCOSIDE; CEFTAZIDIME; CIPROBACTER; CIPROFLOXACIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; KEFADIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; RIFAMPICIN; TAZ PEN; TOBRAMINA; TOBRAMYCIN; UNCLASSIFIED DRUG;

EID: 84879996313     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/0037-8682-0012-2013     Document Type: Article
Times cited : (24)

References (28)
  • 1
    • 77149174778 scopus 로고    scopus 로고
    • Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of pseudomonas aeruginosa
    • Ham VH, Chang KT, Abdelrouf K, Brioso C.G., Ameka M., McCaskey LA, et al Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Chemother 2010; 54:1160-1164.
    • (2010) Antimicrob Chemother , vol.54 , pp. 1160-1164
    • Ham, V.H.1    Chang, K.T.2    Abdelrouf, K.3    Brioso, C.G.4    Ameka, M.5    McCaskey, L.A.6
  • 2
    • 79955527743 scopus 로고    scopus 로고
    • Nosocomial blood stream infections in Brazilian hospitals: Analysis of 2,563 cases from a prospective nationwide surveillance study
    • (Brazilian SCOPE Study Group)
    • Marra AR, Camargo LF, Pignatari A.C., Sukienni KT, Bahar PR, Medeiros EA, et al (Brazilian SCOPE Study Group). Nosocomial blood stream infections in Brazilian hospitals: analysis of 2,563 cases from a prospective nationwide surveillance study. J Clin Microbiol 2011; 49:1866-1871.
    • (2011) J Clin Microbiol , vol.49 , pp. 1866-1871
    • Marra, A.R.1    Camargo, L.F.2    Pignatari, A.C.3    Sukienni, K.T.4    Bahar, P.R.5    Medeiros, E.A.6
  • 3
    • 84872306777 scopus 로고    scopus 로고
    • Phenotypic and molecular characterization of antimicrobial resistance and virulence factors in pseudomonas aeruginosa clinical isolates from recife, state of pernambuco, Brazil
    • Jácome PRLA, Alves LR, Cabrai AB, Lopes ACS, Maciel MAV. Phenotypic and molecular characterization of antimicrobial resistance and virulence factors in Pseudomonas aeruginosa clinical isolates from Recife, State of Pernambuco, Brazil. Rev Soc Bras Med Tropical 2012; 45:707-712.
    • (2012) Rev Soc Bras Med Tropical , vol.45 , pp. 707-712
    • Jácome, P.R.L.A.1    Alves, L.R.2    Cabrai, A.B.3    Lopes, A.C.S.4    Maciel, M.A.V.5
  • 4
    • 84863654489 scopus 로고    scopus 로고
    • Combination therapy for treatment of infections with gram-negative bacteria
    • Tamma PD, Cosgrove SE, Maragakis LL Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 2012;25:450-470.
    • (2012) Clin Microbiol Rev , vol.25 , pp. 450-470
    • Tamma, P.D.1    Cosgrove, S.E.2    Maragakis, L.L.3
  • 5
    • 84455192457 scopus 로고    scopus 로고
    • Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for pseudomonas aeruginosa
    • Drusano GL, Bonomo RA, Bahnink N, Bulitta J.B., Vanscoy B., DeFiglio H, et al Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa. Antimicrob Ag Chemother 2012; 56:231-242.
    • (2012) Antimicrob Ag Chemother , vol.56 , pp. 231-242
    • Drusano, G.L.1    Bonomo, R.A.2    Bahnink, N.3    Bulitta, J.B.4    Vanscoy, B.5    DeFiglio, H.6
  • 7
    • 14944362740 scopus 로고    scopus 로고
    • Performance standards for antimicrobial susceptibility testing
    • Clinical and Laboratory Standards Institute (CLSI) Wayne, PA, USA: CLSI
    • Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. Twentieth Informational Supplement M100-S20. Wayne, PA, USA: CLSI; 2010.
    • (2010) Twentieth Informational Supplement M100-S20
  • 8
    • 77957874402 scopus 로고    scopus 로고
    • [Software]. EUCAST [Version 3.0]
    • European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoints tables for interpretation of MICs and zone diameters [Software]. EUCAST 2013. [Version 3.0]. Available from: http://www.eucast.org/clinical- breakpoints/.
    • (2013) Breakpoints Tables for Interpretation of MICs and Zone Diameters
  • 9
    • 70350279548 scopus 로고    scopus 로고
    • Comparison of the methods to test antibiotic combinations against heterogeneous populations of multiresistant pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis
    • Foweraker JE, Laughton CR, Brown D.F., Bilton D. Comparison of the methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis. Antimicrob Ag Chemother 2009;53:4809-4815.
    • (2009) Antimicrob Ag Chemother , vol.53 , pp. 4809-4815
    • Foweraker, J.E.1    Laughton, C.R.2    Brown, D.F.3    Bilton, D.4
  • 10
    • 70450199336 scopus 로고    scopus 로고
    • Role of old antibiotics in multidrug resistant bacterial infections
    • Maviglia R, Nestorini R, Pennisi M. Role of old antibiotics in multidrug resistant bacterial infections. Curr Drug Targets 2009; 10:895-905.
    • (2009) Curr Drug Targets , vol.10 , pp. 895-905
    • Maviglia, R.1    Nestorini, R.2    Pennisi, M.3
  • 13
    • 79951875467 scopus 로고    scopus 로고
    • Pseudomonas aeruginosa fosfomycin resistance mechanisms affect noninherited fluoroquinolone tolerance
    • De Groote V.N., Faunart M, Kint C.L., Verstaetein N., Jans A, Cornells P, et al Pseudomonas aeruginosa fosfomycin resistance mechanisms affect noninherited fluoroquinolone tolerance. J Med Microbiol 2011; 60: 329-336.
    • (2011) J Med Microbiol , vol.60 , pp. 329-336
    • De Groote, V.N.1    Faunart, M.2    Kint, C.L.3    Verstaetein, N.4    Jans, A.5    Cornells, P.6
  • 14
    • 77956325563 scopus 로고    scopus 로고
    • Assessing the emergence of resistance: The absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections
    • Rodriguez-Rojas A., Maciá MD, Couce A, Goméz C, Castañeda-Garcia A, Oliver A, et al. Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections. PloS One 2010; 5: e10193.
    • (2010) PloS One , vol.5
    • Rodriguez-Rojas, A.1    Maciá, M.D.2    Couce, A.3    Goméz, C.4    Castañeda-Garcia, A.5    Oliver, A.6
  • 15
    • 0141997696 scopus 로고    scopus 로고
    • Dissemination in distint Brazilian regions of an epidemic carbapenem-resistant pseudomonas aeruginosa producing SPM metallo-beta-lactamase
    • Gales AC, Menezes LC, Silbert S, Sader HS Dissemination in distint Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. J Infect Chemother 2003; 52:699-702.
    • (2003) J Infect Chemother , vol.52 , pp. 699-702
    • Gales, A.C.1    Menezes, L.C.2    Silbert, S.3    Sader, H.S.4
  • 16
    • 32644481380 scopus 로고    scopus 로고
    • In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strain pseudomonas aeruginosa and acinetobacter baumannii isolated from intensive care units
    • Timurkaynak F, Can F, Azap O.K., Demirbilek M., Arslan H, Karaman SO In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strain Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006; 27:224-228.
    • (2006) Int J Antimicrob Agents , vol.27 , pp. 224-228
    • Timurkaynak, F.1    Can, F.2    Azap, O.K.3    Demirbilek, M.4    Arslan, H.5    Karaman, S.O.6
  • 17
    • 75749107905 scopus 로고    scopus 로고
    • In vitro efficacy of synergistic antibiotic combinations in multidrug resistant pseudomonas aeruginosa strains
    • Dundar D, Otkum M. In vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains. Yonsei Med J 2010;51:111-116.
    • (2010) Yonsei Med J , vol.51 , pp. 111-116
    • Dundar, D.1    Otkum, M.2
  • 18
    • 67349240825 scopus 로고    scopus 로고
    • Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting gram-negative bacilli: A systematic review of microbiological, animal and clinical studies
    • Falagas MF, Kastoris AC, Karageouropoulos D.E., Rafailidis P. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009; 34:111-120.
    • (2009) Int J Antimicrob Agents , vol.34 , pp. 111-120
    • Falagas, M.F.1    Kastoris, A.C.2    Karageouropoulos, D.E.3    Rafailidis, P.4
  • 20
    • 30344461017 scopus 로고    scopus 로고
    • In vitro activity of fosfomycin-gentamicin, fosfomycin-ceftazidime, fosfomycin-imipenem and ceftazidime-gentamicin combinations against ceftazidime-resistant pseudomonas aeruginosa
    • Pruekpreasert P, Tumiapanit W. In vitro activity of fosfomycin- gentamicin, fosfomycin-ceftazidime, fosfomycin-imipenem and ceftazidime- gentamicin combinations against ceftazidime-resistant Pseudomonas aeruginosa. Southeast Asian Trop Med Publ Health 2005; 36:1239-1242.
    • (2005) Southeast Asian Trop Med Publ Health , vol.36 , pp. 1239-1242
    • Pruekpreasert, P.1    Tumiapanit, W.2
  • 21
    • 34147214218 scopus 로고    scopus 로고
    • Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of pseudomonas aeruginosa
    • Yamada S, Hyo Y, Ohuori M. Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosa. Chemotherapy 2007; 53:202-209.
    • (2007) Chemotherapy , vol.53 , pp. 202-209
    • Yamada, S.1    Hyo, Y.2    Ohuori, M.3
  • 22
    • 0023274446 scopus 로고
    • Synergy of impenem - A novel carbapenem, and rifampin and ciprofloxacin against pseudomonas aeruginosa, serratia marcescens and enterobacter species
    • Chin NX, Neu HC Synergy of impenem - a novel carbapenem, and rifampin and ciprofloxacin against Pseudomonas aeruginosa, Serratia marcescens and Enterobacter species. Chemotherapy 1987; 33:183-188.
    • (1987) Chemotherapy , vol.33 , pp. 183-188
    • Chin, N.X.1    Neu, H.C.2
  • 23
    • 0025323118 scopus 로고
    • The effect of rifampicin on the in vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against pseudomonas aeruginosa
    • Valdes JM, Baltch AL, Smith R.P., Hammer MC, Ritz WJ The effect of rifampicin on the in vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosa. J Antimicrob Chemother 1990; 25:575-584.
    • (1990) J Antimicrob Chemother , vol.25 , pp. 575-584
    • Valdes, J.M.1    Baltch, A.L.2    Smith, R.P.3    Hammer, M.C.4    Ritz, W.J.5
  • 24
    • 0029896104 scopus 로고    scopus 로고
    • The effect of rifampicin on adaptative resistance of pseudomonas aeruginosa to aminoglycosides
    • Xiong YQ, Caillon J, Drugcon H., Potel G, Baron D. The effect of rifampicin on adaptative resistance of Pseudomonas aeruginosa to aminoglycosides. J Antimicrob Chemother 1996; 37:993-998.
    • (1996) J Antimicrob Chemother , vol.37 , pp. 993-998
    • Xiong, Y.Q.1    Caillon, J.2    Drugcon, H.3    Potel, G.4    Baron, D.5
  • 25
    • 0038345558 scopus 로고    scopus 로고
    • In vitro interaction of colistin and rifampin on multidrug resistant pseudomonas aeruginosa
    • Giamarellos-Bourbouilis E.J., Sambatakon H, Galani I., Giamarellou H. In vitro interaction of Colistin and rifampin on multidrug resistant Pseudomonas aeruginosa. J Chemother 2003; 15:235-238.
    • (2003) J Chemother , vol.15 , pp. 235-238
    • Giamarellos-Bourbouilis, E.J.1    Sambatakon, H.2    Galani, I.3    Giamarellou, H.4
  • 26
    • 0028828457 scopus 로고
    • Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by pseudomonas aeruginosa
    • Weiss K, Lapointe JR Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa. Antimicrob Ag Chemother 1995; 39:2411-2414.
    • (1995) Antimicrob Ag Chemother , vol.39 , pp. 2411-2414
    • Weiss, K.1    Lapointe, J.R.2
  • 27
    • 44949084345 scopus 로고    scopus 로고
    • In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distint multidrug-resistant isolates of pseudomonas aeruginosa
    • Kanellakopoulou K, Sarafis P, Galani I., Giamarellou H, Giamarellos-Bourboulis EJ. In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distint multidrug-resistant isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 2008; 32:33-39.
    • (2008) Int J Antimicrob Agents , vol.32 , pp. 33-39
    • Kanellakopoulou, K.1    Sarafis, P.2    Galani, I.3    Giamarellou, H.4    Giamarellos-Bourboulis, E.J.5
  • 28
    • 77749243224 scopus 로고    scopus 로고
    • Quantitative assestment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model
    • Yuan Z, Ledesma KR, Singh R, Prince R.A., Tam VH Quantitative assestment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. J Infect Dis 2010; 201:889-897.
    • (2010) J Infect Dis , vol.201 , pp. 889-897
    • Yuan, Z.1    Ledesma, K.R.2    Singh, R.3    Prince, R.A.4    Tam, V.H.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.